CL2021003498A1 - Compuesto de pirazolona y pirimidina, y método de preparación y uso del mismo - Google Patents

Compuesto de pirazolona y pirimidina, y método de preparación y uso del mismo

Info

Publication number
CL2021003498A1
CL2021003498A1 CL2021003498A CL2021003498A CL2021003498A1 CL 2021003498 A1 CL2021003498 A1 CL 2021003498A1 CL 2021003498 A CL2021003498 A CL 2021003498A CL 2021003498 A CL2021003498 A CL 2021003498A CL 2021003498 A1 CL2021003498 A1 CL 2021003498A1
Authority
CL
Chile
Prior art keywords
pyrazolone
preparation
pyrimidine compound
pyrimidine
compound
Prior art date
Application number
CL2021003498A
Other languages
English (en)
Inventor
Zhihui Zhang
Qian Wang
Guoyong Huo
Guangxin Xia
Jiangsong Lou
Sijie Shu
Hui Ge
Lin Zhang
Chen Shi
Yu Mao
Bingbin Zhang
Jianxin Yu
Yanjun Liu
Ying Ke
Chi Zhang
Original Assignee
Shanghai Pharmaceuticals Holding Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Pharmaceuticals Holding Co Ltd filed Critical Shanghai Pharmaceuticals Holding Co Ltd
Publication of CL2021003498A1 publication Critical patent/CL2021003498A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2021003498A 2019-06-28 2021-12-27 Compuesto de pirazolona y pirimidina, y método de preparación y uso del mismo CL2021003498A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910578299 2019-06-28

Publications (1)

Publication Number Publication Date
CL2021003498A1 true CL2021003498A1 (es) 2022-08-19

Family

ID=73889014

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021003498A CL2021003498A1 (es) 2019-06-28 2021-12-27 Compuesto de pirazolona y pirimidina, y método de preparación y uso del mismo

Country Status (13)

Country Link
US (1) US20220324868A1 (es)
EP (1) EP4008719A4 (es)
JP (1) JP2022539460A (es)
KR (1) KR20230046270A (es)
CN (1) CN112142748B (es)
AU (1) AU2020304472A1 (es)
BR (1) BR112021026620A2 (es)
CA (1) CA3145348A1 (es)
CL (1) CL2021003498A1 (es)
CO (1) CO2022000751A2 (es)
IL (1) IL289395A (es)
MX (1) MX2022000199A (es)
WO (1) WO2020259724A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7300460B2 (ja) 2018-03-09 2023-06-29 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー 置換１，２－ジヒドロ－３Ｈ－ピラゾロ［３，４－ｄ］ピリミジン－３－オン
IL298201A (en) * 2020-05-15 2023-01-01 Recurium Ip Holdings Llc Single and combined treatments
CN114591334B (zh) * 2020-12-04 2023-10-20 山东轩竹医药科技有限公司 二氢吡唑并嘧啶酮衍生物
WO2022251224A1 (en) * 2021-05-28 2022-12-01 Recurium Ip Holdings, Llc Wee1 inhibitors and methods for treating cancer
CN117751122A (zh) * 2021-08-11 2024-03-22 微境生物医药科技(上海)有限公司 作为Wee-1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮化合物
AU2022384370A1 (en) * 2021-11-09 2024-06-13 Hangzhou Glubio Pharmaceutical Co. Ltd. Wee1 protein kinase degradation agent and use thereof
WO2023193789A1 (en) * 2022-04-08 2023-10-12 Beijing Neox Biotech Limited Wee1 degrading compounds

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003251010A1 (en) 2002-07-15 2004-02-02 Janssen Pharmaceutica N.V. 3-furanyl analogs of toxoflavine as kinase inhibitors
AR060635A1 (es) 2006-04-27 2008-07-02 Banyu Pharma Co Ltd Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer
WO2008115742A1 (en) 2007-03-20 2008-09-25 Smithkline Beecham Corporation Chemical compounds
CA2681248A1 (en) 2007-03-20 2008-09-25 Smithkline Beecham Corporation Chemical compounds
CA2745970A1 (en) 2008-12-12 2010-06-17 Msd K.K. Dihydropyrimidopyrimidine derivative
JP2012518598A (ja) 2009-02-25 2012-08-16 Ｍｓｄ株式会社 ピリミドピリミドインダゾール誘導体
CA3003737C (en) * 2015-11-01 2021-09-14 The Regents Of The University Of Colorado, A Body Corporate Wee1 kinase inhibitors and methods of making and using the same
WO2018133829A1 (zh) * 2017-01-23 2018-07-26 南京明德新药研发股份有限公司 作为Wee1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮衍生物
AU2018312448B2 (en) * 2017-08-01 2022-09-15 Recurium Ip Holdings, Llc 1, 2 - dihydro- 3h- pyrazolo [3, 4 - d] pyrimidin -3 - one analogs
WO2019037678A1 (zh) 2017-08-24 2019-02-28 上海迪诺医药科技有限公司 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用
US11299493B2 (en) * 2017-10-09 2022-04-12 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
CN109810111B (zh) * 2017-11-20 2023-10-27 上海医药集团股份有限公司 一种吡唑酮并嘧啶类化合物、其制备方法及应用
JP7300460B2 (ja) * 2018-03-09 2023-06-29 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー 置換１，２－ジヒドロ－３Ｈ－ピラゾロ［３，４－ｄ］ピリミジン－３－オン

Also Published As

Publication number Publication date
EP4008719A4 (en) 2023-03-22
WO2020259724A2 (zh) 2020-12-30
CN112142748A (zh) 2020-12-29
EP4008719A2 (en) 2022-06-08
AU2020304472A1 (en) 2022-03-03
KR20230046270A (ko) 2023-04-05
CA3145348A1 (en) 2020-12-30
WO2020259724A3 (zh) 2021-02-18
MX2022000199A (es) 2022-09-29
JP2022539460A (ja) 2022-09-09
CO2022000751A2 (es) 2022-04-29
IL289395A (en) 2022-02-01
BR112021026620A2 (pt) 2022-06-07
US20220324868A1 (en) 2022-10-13
CN112142748B (zh) 2023-07-04

Similar Documents

Publication Publication Date Title
CL2021003498A1 (es) Compuesto de pirazolona y pirimidina, y método de preparación y uso del mismo
CL2020000281A1 (es) Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39 y métodos de uso de anticuerpos anti-cd39
CL2017003486A1 (es) Lactamas bicíclicas y métodos de uso de las mismas
EP3310339A4 (en) OPHTHALMIC FORMULATIONS OF TYROSINE KINASE INHIBITORS, METHOD OF USE THEREOF AND METHOD OF PRODUCTION THEREOF
ECSP17030878A (es) Formas cristalinas de 5-cloro-n4-[2-(dimetilfosforil)fenil]-n2-{2-metoxi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]pirimidina-2,4-diamina
CR20140460A (es) Formas polimórficas de (s)-2-(1-(9h-purin-6-ilamino)propil)-5-fluoro-3-fenilquinazolin-4(3h)-ona
EP3246328A4 (en) Quinazoline heterocyclic compound as egfr kinase inhibitor, and preparation and application thereof
NI201500119A (es) Compuestos de heteroarilo y sus usos
ES2974248T3 (es) Compuesto de pirimidin-piperazina sustituido y uso del mismo
CL2018001139A1 (es) Anticuerpos anti-htra1 y métodos de uso de los mismos.
SG11202103104RA (en) Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies
ES2974267T3 (es) Uso de composición refrigerante
CL2020002333A1 (es) Anticuerpos anti-klk5 y métodos de uso.
EP3354653A4 (en) Fused ring pyrimidine compound, intermediate, and preparation method, composition and use thereof
EP3255046A4 (en) Hydroxyethyl sulfonate of cyclin-dependent protein kinase inhibitor, crystalline form thereof and preparation method therefor
DK3412673T3 (da) Fremgangsmåde til fremstilling af pyrrolo[3,2-D]pyrimidin-forbindelse og mellemprodukter deraf
IT201600090975A1 (it) Gruppo valvola di fondo pozzo e metodo di utilizzo dello stesso
ECSP21021189A (es) Formas de dosificación pediátricas de vitamina d, métodos de elaboración y uso
DK3962601T3 (da) 5-HT2A-agonister til anvendelse til behandling af depression
EP3798218A4 (en) FUSED CYCLIC FORMAMIDE PYRAZOLONE COMPOUND, METHOD FOR PREPARATION, PHARMACEUTICAL COMPOSITION AND USE THEREOF
ES2974003T3 (es) Derivado de la formilpiridina con actividad inhibidora del FGFR4, método de preparación y uso del mismo
DK3765440T3 (da) Fremgangsmåde til fremstilling af n-alkyl-nitratoethylnitraminer
CL2018000428A1 (es) Procedimiento de preparación de los metabolitos de (4s) y (4r)-4-(4-ciano-2-metoxifenil)-5-etoxi-2,8-dimetil-1,4-dihidro-1,6-naftiridina-3-carboxamida y uso de los mismos
CO2019011980A2 (es) Formas cristalinas de (s)-afoxolaner
EP3719015A4 (en) SUBSTITUTED PYRIMIDINE COMPOUND AND MANUFACTURING METHOD FOR ITS AND USES THEREOF